These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24091715)

  • 1. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
    Vejpongsa P; Yeh ET
    Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
    Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
    Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
    Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
    Zhang S; Liu X; Bawa-Khalfe T; Lu LS; Lyu YL; Liu LF; Yeh ET
    Nat Med; 2012 Nov; 18(11):1639-42. PubMed ID: 23104132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.
    Henninger C; Fritz G
    Cell Death Dis; 2017 Jan; 8(1):e2564. PubMed ID: 28102848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.
    Menna P; Salvatorelli E
    Chemotherapy; 2017; 62(3):159-168. PubMed ID: 28122377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The flavonoid quercetin: possible solution for anthracycline-induced cardiotoxicity and multidrug resistance.
    Czepas J; Gwoździński K
    Biomed Pharmacother; 2014 Oct; 68(8):1149-59. PubMed ID: 25458790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
    Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
    Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranolazine in the prevention of anthracycline-related cardiotoxicity].
    Corradi F; Paolini L; De Caterina R
    G Ital Cardiol (Rome); 2013 Jun; 14(6):424-37. PubMed ID: 23748539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
    Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
    Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.